Bayer recently opened an expansion of its pharmaceutical products supply site in Beijing, Global Times reported Thursday.
The expansion at the facility, at a cost of 100 million euros will allow Bayer to double production capacity, including products such as Adalat, Bayaspirin and Glucobay.
The investment comes after the World Health Organization in 2013 called on countries and regions to reduce premature deaths from non-communicable diseases by 25 percent by 2025.
Meanwhile, China set a target of a 30-percent decline in premature death from chronic diseases by 2030.
To read more NewsPoints articles, click here.